Intravenous injection employ persons hepatitis B immune globulin and method of preparing the same

An immunoglobulin and hepatitis B technology, which is applied in the preparation methods of antiviral immunoglobulin, serum immunoglobulin and peptide, etc., can solve the problems of high price, complicated process, unsuitable scale production, etc., and can meet the supply of plasma , the effect of improving the survival rate and overcoming the bottleneck of process scale-up

Active Publication Date: 2010-10-27
广东双林生物制药有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The current preparation of human hepatitis B immunoglobulin for intravenous injection is complicated and requires special equipment, which is not suitable for large-scale production, so the price is expensive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Intravenous injection employ persons hepatitis B immune globulin and method of preparing the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] The present invention will be further described through specific examples below, but the present invention is not limited to this specific example.

[0024] 1. Preparation of human hepatitis B immunoglobulin raw material plasma for intravenous injection

[0025] Select plasma donors who meet the national apheresis plasma donation standards, use 3 needles for one tube each time, and the content of hepatitis B vaccine is 10 mg per tube, and give plasma donors injections of hepatitis B vaccine for basic immunization in 0, 1, and 6 months. Plasma donors who are positive for hepatitis B surface antibody after basic immunization will be injected with hepatitis B vaccine for booster immunization 6 months after the completion of basic immunization. After 14 days of booster immunization, plasma from healthy people with a titer of hepatitis B antibody greater than 8IU / ml will be collected. The plasma collection process is in accordance with the Ministry of Health "Technical Requi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses hepatitis B immunoglobulin used in intravenous injection and a preparation method thereof. The hepatitis B immunoglobulin used in intravenous injection comprises a high-titer hepatitis B virus antibody, and the content of the immunoglobulin is not less than 95.0 percent of the total protein content; the titer of the hepatitis B antibody is more than 50IU / ml, and the sum ofan IgG monomer and a dimmer is not less than 95 percent; the hepatitis B immunoglobulin is prepared through the multi-step separation, virus inactivation, ultra-filtration and dealcoholization and the filling of the raw plasma. The hepatitis B immunoglobulin used in intravenous injection is an effective drug used for preventing the patients with liver transplantation from being re-infected by thehepatitis B virus, and can obviously reduce the hepatitis B virus infection rate of the patients with liver transplantation and improve the survival rate of the patients; By overcoming the present technical bottleneck and adopting the unique process parameter control, the preparation process can produce immunoglobulin with anti-hepatitis B specificity with a conventional device of cold ethanol precipitation and pressure filtration and separation, and is suitable for scale industrial production. The products have good anti-hepatitis B activity, and are safe and reliable.

Description

technical field [0001] The invention relates to a human hepatitis B immunoglobulin for intravenous injection and a preparation method thereof. Background technique [0002] There are at least 350 million people in the world who carry hepatitis B virus (HBV), and 300 million liver cirrhosis is related to HBV infection. my country is a high-incidence area for HBV infection. The positive rate of hepatitis B surface antigen (HBsAg) in the population is 9.75%. HBsAg carriers 120 million people; among HBV carriers, a quarter will develop chronic liver disease. Based on this calculation, there are no less than 30 million people with chronic hepatitis B liver disease in the country. If these patients are not treated in time, they will further develop into liver disease. The probability of fibrosis, liver cirrhosis and even liver cancer is relatively high, and it can be transmitted to infants and children through mother to child, affecting the health of the next generation and causing ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/42A61K9/08A61K9/19C07K16/06C07K16/08C07K1/14
Inventor 朱光祖吕应年黄荣强蒋桂香郑文东王明明
Owner 广东双林生物制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap